[ Ref ID: 47 ] Address - SG -,
The au courant trend is now ‘shared risk and opportunities for shared reward’. The shift in mindset driving this trend is subtle; to succeed, it implies if not an explicit partnership then an implicit compromise between parties such as small biotech and big pharma, and drug developer and payor. The ramifications of this shift, which will encompass every player in the biopharma drug development ecosystem, are already influencing dealmaking decisions.
:
The increased cost of drug development has also impelled pharmaceutical companies to seek better opportunities in emerging markets to successfully expand their R&D pipeline and products. Emerging markets is seen by many as lucrative due to their economical infrastructure and manpower costs and a significant untapped market potential with a large population.
The deals of tomorrow will emphasize on bespoke arrangements that mirror the tailoring of medicines to individual patients. Convergence is inevitable across the industry – the pharmas, generics, biotechs, medical devices, hospitals, technology providers, healthcare and wellness organizations are now looking into more innovative ways to meet the changing trends of the life sciences and healthcare industry. As a result, the biopharma industry is seeing a globalised, cross border convergence with every player in the industry actively seeking out innovative strategic alliances to meet their corporate objectives.
This niche and timely conference provides the perfect networking platform for top level decision makers and facilitates important discussions and exchange of ideas on the trends and opportunities of this lucrative and fast changing industry.
Participation Price:
For more information about the price please call us tel:+421 944 263926